| Autor: |
Balaphas, Alexandre, Belfontali, Valentina, Ris, Frédéric, Lanitis, Andreas, Meier, Raphaël, Amram, Marie-Laure, Roth, Arnaud, Huber, Olivier, Berney, Thierry, Morel, Philippe |
| Jazyk: |
francouzština |
| Rok vydání: |
2016 |
| Předmět: |
|
| Zdroj: |
Revue médicale suisse, Vol. 12, No 523 (2016) pp. 1190-1194 |
| ISSN: |
1660-9379 |
| Popis: |
In 2016, peritoneal carcinomatosis can be considered as a chronic disease that can be treated and sometimes cured. Hyperthermic Intra PEritoneal Chemotherapy (HIPEC) is a procedure developed in the eighties. Combined with CytoReductive (CR) surgery, this protocol underwent a considerable expansion in Washington Cancer Institute. CR combined with HIPEC was demonstrated to be the only curative treatment for PseudoMyxoma Peritonei syndrome (PMP). It is actually approved in the management of peritoneal carcinomatosis of ovarian, colorectal, or peritoneal primitive (mesothelioma) origin but is still studied for gastric cancer. CR/HIPEC is associated with an important mortality and morbidity. This article takes stock of indications to CR/HIPEC. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
